Literature DB >> 25600946

drexplorer: A tool to explore dose-response relationships and drug-drug interactions.

Pan Tong1, Kevin R Coombes1, Faye M Johnson1, Lauren A Byers1, Lixia Diao1, Diane D Liu1, J Jack Lee1, John V Heymach1, Jing Wang1.   

Abstract

MOTIVATION: Nonlinear dose-response models are primary tools for estimating the potency [e.g. half-maximum inhibitory concentration (IC) known as IC50] of anti-cancer drugs. We present drexplorer software, which enables biologists to evaluate replicate reproducibility, detect outlier data points, fit different models, select the best model, estimate IC values at different percentiles and assess drug-drug interactions. drexplorer serves as a computation engine within the R environment and a graphical interface for users who do not have programming backgrounds.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Mesh：

Substances：

Year:  2015        PMID： 25600946      PMCID： PMC4426846          DOI： 10.1093/bioinformatics/btv028

Source DB:  PubMed          Journal:  Bioinformatics        ISSN： 1367-4803            Impact factor:   6.937


  6 in total

1.  Interaction index and different methods for determining drug interaction in combination therapy.

Authors:  J J Lee; M Kong; G D Ayers; R Lotan
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

2.  Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction.

Authors:  J Jack Lee; Maiying Kong
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

3.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

4.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

5.  Synergistic drug combinations tend to improve therapeutically relevant selectivity.

Authors:  Joseph Lehár; Andrew S Krueger; William Avery; Adrian M Heilbut; Lisa M Johansen; E Roydon Price; Richard J Rickles; Glenn F Short; Jane E Staunton; Xiaowei Jin; Margaret S Lee; Grant R Zimmermann; Alexis A Borisy
Journal:  Nat Biotechnol       Date:  2009-07-05       Impact factor: 54.908

6.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971
  6 in total
  13 in total

1.  Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.

Authors:  Triparna Sen; Pan Tong; Lixia Diao; Lerong Li; Youhong Fan; Jennifer Hoff; John V Heymach; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

2.  CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Authors:  Triparna Sen; Pan Tong; C Allison Stewart; Sandra Cristea; Aly Valliani; David S Shames; Abena B Redwood; You Hong Fan; Lerong Li; Bonnie S Glisson; John D Minna; Julien Sage; Don L Gibbons; Helen Piwnica-Worms; John V Heymach; Jing Wang; Lauren Averett Byers
Journal:  Cancer Res       Date:  2017-05-10       Impact factor: 12.701

3.  Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.

Authors:  Ming Zhang; Ratnakar Singh; Shaohua Peng; Tuhina Mazumdar; Vaishnavi Sambandam; Li Shen; Pan Tong; Lerong Li; Nene N Kalu; Curtis R Pickering; Mitchell Frederick; Jeffrey N Myers; Jing Wang; Faye M Johnson
Journal:  Cancer Lett       Date:  2017-01-23       Impact factor: 8.679

4.  Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.

Authors:  Renata Ferrarotto; Ruchitha Goonatilake; Suk Young Yoo; Pan Tong; Uma Giri; Shaohua Peng; John Minna; Luc Girard; Yuehong Wang; Liguang Wang; Lerong Li; Lixia Diao; David H Peng; Don L Gibbons; Bonnie S Glisson; John V Heymach; Jing Wang; Lauren A Byers; Faye M Johnson
Journal:  Clin Cancer Res       Date:  2015-11-23       Impact factor: 12.531

5.  Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.

Authors:  Robert J Cardnell; Ying Feng; Seema Mukherjee; Lixia Diao; Pan Tong; C Allison Stewart; Fatemeh Masrorpour; YouHong Fan; Monique Nilsson; Yuqiao Shen; John V Heymach; Jing Wang; Lauren A Byers
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

6.  Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.

Authors:  Shaohua Peng; Banibrata Sen; Tuhina Mazumdar; Lauren A Byers; Lixia Diao; Jing Wang; Pan Tong; Uma Giri; John V Heymach; Humam N Kadara; Faye M Johnson
Journal:  Oncotarget       Date:  2016-01-05

7.  Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin.

Authors:  Byunghee Yoo; Patricia Greninger; Giovanna T Stein; Regina K Egan; Joseph McClanaghan; Anna Moore; Cyril H Benes; Zdravka Medarova
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

8.  Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.

Authors:  Yuehong Wang; Ratnakar Singh; Liguang Wang; Monique Nilsson; Ruchitha Goonatilake; Pan Tong; Lerong Li; Uma Giri; Pamela Villalobos; Barbara Mino; Jaime Rodriguez-Canales; Ignacio Wistuba; Jing Wang; John V Heymach; Faye M Johnson
Journal:  Oncotarget       Date:  2016-07-26

9.  Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities.

Authors:  John D Lapek; Patricia Greninger; Robert Morris; Arnaud Amzallag; Iulian Pruteanu-Malinici; Cyril H Benes; Wilhelm Haas
Journal:  Nat Biotechnol       Date:  2017-09-11       Impact factor: 54.908

10.  AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.

Authors:  Kavya Ramkumar; C Allison Stewart; Kasey R Cargill; Carminia M Della Corte; Qi Wang; Li Shen; Lixia Diao; Robert J Cardnell; David H Peng; B Leticia Rodriguez; You-Hong Fan; John V Heymach; Jing Wang; Carl M Gay; Don L Gibbons; Lauren A Byers
Journal:  Mol Cancer Res       Date:  2020-11-10       Impact factor: 6.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.